Literature DB >> 21724304

Synthesis, characterization and anticancer studies of mixed ligand dithiocarbamate palladium(II) complexes.

Hizbullah Khan1, Amin Badshah, Ghulam Murtaz, Muhammad Said, Zia-ur- Rehman, Christine Neuhausen, Margarita Todorova, Bertrand J Jean-Claude, Ian S Butler.   

Abstract

Six mixed ligand dithiocarbamate Pd(II) complexes (1-6) of general formula [(DT)Pd(PR(3))Cl], where DT = dimethyldithiocarbamate (1, 5), diethyldithiocarbamate (2, 3), dicyclohexyldithiocarbamate (4), bis(2-methoxyethyl)dithiocarbamate (6); PR(3) = benzyldiphenylphosphine (1), diphenyl-2-methoxyphenylphosphine (2), diphenyl-p-tolylphosphine (3), diphenyl-m-tolylphosphine (4), tricyclohexylphosphine (5), diphenyl-2-pyridylphosphine (6) have been synthesized and characterised using Elemental analysis, FT-IR, Raman and multinuclear magnetic resonance (NMR) spectroscopy. Compounds 1 and 2 were also characterized by single crystal X-ray diffraction technique (XRD). The XRD study reveals that the Pd(II) moiety has a pseudo square-planar geometry, in which two positions are occupied by the dithiocarbamate ligand in a bidentate fashion, while at the remaining two positions organophosphine and chloride are present. The anticancer activity of the synthesized metallodrugs was checked against DU145 human prostate carcinoma (HTB-81) cells, the IC(50) values indicate that the compounds are highly active against these cells. These Pd(II) complexes also show moderate antibacterial activity against gram positive and gram negative bacteria.
Copyright © 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21724304     DOI: 10.1016/j.ejmech.2011.06.007

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  7 in total

1.  Investigating the Apoptosis Ability of Ethylenediamine 8-Hydroxyquinolinato Palladium (II) Complex.

Authors:  Hassan Mansouri-Torshizi; Elham Rezaei; Farzaneh Kamranfar; Mostafa Heidari Majd
Journal:  Adv Pharm Bull       Date:  2016-09-25

2.  A General Approach to Site-Specific, Intramolecular C-H Functionalization Using Dithiocarbamates.

Authors:  Christina G Na; Erik J Alexanian
Journal:  Angew Chem Int Ed Engl       Date:  2018-09-03       Impact factor: 15.336

3.  Synthesis and Characterization of New Palladium(II) Thiosemicarbazone Complexes and Their Cytotoxic Activity against Various Human Tumor Cell Lines.

Authors:  Wilfredo Hernández; Juan Paz; Fernando Carrasco; Abraham Vaisberg; Evgenia Spodine; Jorge Manzur; Lothar Hennig; Joachim Sieler; Steffen Blaurock; Lothar Beyer
Journal:  Bioinorg Chem Appl       Date:  2013-12-11       Impact factor: 7.778

4.  Synthesis, Structural Characterization, and Evaluation of the Biological Properties of Heteroleptic Palladium(II) Complexes.

Authors:  Hizbullah Khan; Nek Daraz; Muhammad Nasim Khan; Muhammad Said; Nosheen Akhtar; Amin Badshah; Amir Sada Khan; Murad Ali
Journal:  Bioinorg Chem Appl       Date:  2014-09-07       Impact factor: 7.778

5.  Melatonin Enhances Palladium-Nanoparticle-Induced Cytotoxicity and Apoptosis in Human Lung Epithelial Adenocarcinoma Cells A549 and H1229.

Authors:  Sangiliyandi Gurunathan; Muniyandi Jeyaraj; Min-Hee Kang; Jin-Hoi Kim
Journal:  Antioxidants (Basel)       Date:  2020-04-24

6.  Thiol-Functionalized Ethylene Periodic Mesoporous Organosilica as an Efficient Scavenger for Palladium: Confirming the Homogeneous Character of the Suzuki Reaction.

Authors:  María I López; Dolores Esquivel; César Jiménez-Sanchidrián; Pascal Van Der Voort; Francisco J Romero-Salguero
Journal:  Materials (Basel)       Date:  2020-01-30       Impact factor: 3.623

7.  Differential cytotoxic activity of a novel palladium-based compound on prostate cell lines, primary prostate epithelial cells and prostate stem cells.

Authors:  Engin Ulukaya; Fiona M Frame; Buse Cevatemre; Davide Pellacani; Hannah Walker; Vincent M Mann; Matthew S Simms; Michael J Stower; Veysel T Yilmaz; Norman J Maitland
Journal:  PLoS One       Date:  2013-05-10       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.